Feasibility and safety of paclitaxel-eluting balloon for the treatment of de novo coronary lesions
10.3760/cma.j.issn.0253-3758.2018.01.007
- VernacularTitle: 紫杉醇洗脱球囊治疗冠状动脉原发病变的安全性和可行性
- Author:
Zhonghan NI
1
;
Wenhui HUANG
;
Yuan LIU
;
Zhujun CHEN
;
Jie LI
;
Junqing YANG
;
Pengcheng HE
;
Yingling ZHOU
;
Jiyan CHEN
;
Jianfang LUO
Author Information
1. Department of Cardiology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangzhou 510080, China
- Publication Type:Journal Article
- Keywords:
Coronary artery disease;
Treatment outcome;
Paclitaxel-eluting balloon
- From:
Chinese Journal of Cardiology
2018;46(1):39-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety and feasibility of treating de novo coronary lesions with paclitaxel-eluting balloon.
Methods:This is a retrospective study, which enrolled 76 patients with 80 de novo coronary lesions treated with paclitaxel-eluting balloons(<30% residual stenosis and there was no blood flow limited dissection after pretreatment) from April 2015 to November 2016 in Guangdong general hospital. The data of basic characteristics,procedures,devices and follow-up information were retrieved and analyzed. The primary endpoint was the composite of cardiac death, recurrent myocardial infarction and target lesion revascularization.
Results:(1)The age was (63.3±10.3) years. There were 68.4%(52/76) acute coronary syndrome patients, prevalence of type 2 diabetes was 36.8%(28/76), and 64.5%(49/76)patients with at least one high bleeding risk. (2)The lesion length was (17.4±7.6)mm, and the stenosis was (88.1±8.2)%.The reference vessel diameter≥2.75 mm accounted for 51.2% (41/80), and bifurcation stenosis accounted for 67.5%(54/80). (3)53.7%(43/80) lesions were pretreated with scoring balloon to optimize plaque modification. The paclitaxel-eluting balloon length and diameter were (22.3±5.5)mm and (2.74±0.52)mm.The residual stenosis was (12.3±10.3)%. Procedural success was 88.8%(71/80).Bail-out stenting rate was 5.0%(4/80). (4)The median follow-up duration was 12(6, 25) months. Primary endpoint occurred in 3 cases (3.9%), including 2 cardiac deaths(1 patient died of recurrent myocardial infarction, and 1 patient died of acute heart failure induced by severe mitral insufficiency), and one patient receivedtarget lesion revascularization.
Conclusion:In case of no more than 30% residual stenosis and no blood flow limited dissection after lesion pretreatment,it is safe and feasible to treat de novo coronary lesionsusing paclitaxel-eluting balloon.
